Citi lowered the firm’s price target on Merck (MRK) to $125 from $130 and keeps a Buy rating on the shares. Ahead of the Q4 earnings, the firm updated models for its biotechnology and pharmaceuticals coverage. Higher-growth names like Eli Lilly (LLY) and Vertex VRTX) remain Citi’s favorites in the group, given their “strong demand” in key franchises and a lower impact from potential policy changes. The sector “looks tricky” in 2025 given negative sentiment, but growth expectations appear beatable with a focus on commercial execution, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Adagene announces updated data from Phase 1b/2 study of muzastotug, keytruda
- Merck: FDA grants priority review to sNDA for Welireg
- Merck, Eisai provide update on Phase 3 LEAP-015 trial
- Trump Trade: Musk plays down Stargate AI investment announcement
- Kennedy Jr. to keep vaccine suit stake if confirmed as health chief, FT says